Edskes Herman K, Stroobant Emily E, DeWilde Morgan P, Bezsonov Evgeny E, Wickner Reed B
Laboratory of Biochemistry and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0830, USA.
Genetics. 2021 May 17;218(1). doi: 10.1093/genetics/iyab037.
[URE3] is a prion of the nitrogen catabolism controller, Ure2p, and [PSI+] is a prion of the translation termination factor Sup35p in S. cerevisiae. Btn2p cures [URE3] by sequestration of Ure2p amyloid filaments. Cur1p, paralogous to Btn2p, also cures [URE3], but by a different (unknown) mechanism. We find that an array of mutations impairing proteasome assembly or MG132 inhibition of proteasome activity result in loss of [URE3]. In proportion to their prion-curing effects, each mutation affecting proteasomes elevates the cellular concentration of the anti-prion proteins Btn2 and Cur1. Of >4,600 proteins detected by SILAC, Btn2p was easily the most overexpressed in a pre9Δ (α3 core subunit) strain. Indeed, deletion of BTN2 and CUR1 prevents the prion-curing effects of proteasome impairment. Surprisingly, the 15 most unstable yeast proteins are not increased in pre9Δ cells suggesting altered proteasome specificity rather than simple inactivation. Hsp42, a chaperone that cooperates with Btn2 and Cur1 in curing [URE3], is also necessary for the curing produced by proteasome defects, although Hsp42p levels are not substantially altered by a proteasome defect. We find that pre9Δ and proteasome chaperone mutants that most efficiently lose [URE3], do not destabilize [PSI+] or alter cellular levels of Sup35p. A tof2 mutation or deletion likewise destabilizes [URE3], and elevates Btn2p, suggesting that Tof2p deficiency inactivates proteasomes. We suggest that when proteasomes are saturated with denatured/misfolded proteins, their reduced degradation of Btn2p and Cur1p automatically upregulates these aggregate-handling systems to assist in the clean-up.
[URE3]是酿酒酵母中氮分解代谢调控因子Ure2p的一种朊病毒,而[PSI+]是翻译终止因子Sup35p的一种朊病毒。Btn2p通过隔离Ure2p淀粉样细丝治愈[URE3]。与Btn2p同源的Cur1p也能治愈[URE3],但其作用机制不同(未知)。我们发现,一系列损害蛋白酶体组装或用MG132抑制蛋白酶体活性的突变会导致[URE3]丢失。与它们的朊病毒治愈效果成比例,每个影响蛋白酶体的突变都会提高抗朊病毒蛋白Btn2和Cur1的细胞浓度。在通过稳定同位素标记氨基酸法(SILAC)检测到的4600多种蛋白质中,Btn2p在pre9Δ(α3核心亚基)菌株中是最易过度表达的。实际上,删除BTN2和CUR1可阻止蛋白酶体损伤的朊病毒治愈效果。令人惊讶的是,pre9Δ细胞中15种最不稳定的酵母蛋白并未增加,这表明蛋白酶体特异性发生了改变,而非简单的失活。Hsp42是一种伴侣蛋白,在治愈[URE3]时与Btn2和Cur1协同作用,它对于蛋白酶体缺陷产生的治愈作用也是必需的,尽管蛋白酶体缺陷不会使Hsp42p水平发生显著改变。我们发现,最有效地丢失[URE3]的pre9Δ和蛋白酶体伴侣突变体并不会使[PSI+]不稳定,也不会改变Sup35p的细胞水平。A tof2突变或缺失同样会使[URE3]不稳定,并提高Btn2p水平,这表明Tof2p缺乏会使蛋白酶体失活。我们认为,当蛋白酶体被变性/错误折叠的蛋白质饱和时,它们对Btn2p和Cur1p降解的减少会自动上调这些聚集体处理系统,以协助清理工作。